GlaxoSmithKline to Partner With US Company Alector on Neurodegenerative-Disease Drugs
July 02 2021 - 6:51AM
Dow Jones News
By Cecilia Butini
GlaxoSmithKline PLC said Friday that it is entering into a
strategic collaboration with U.S.-based company Alector Inc. for
the development of two drugs for the potential treatment of
neurodegenerative diseases, including Alzheimer's.
The deal is worth $700 million plus an additional $1.5 billion
in milestone payments from GlaxoSmithKline to Alector if the drugs
prove successful in clinical trials and are approved for use, the
company said.
The drugs are two monoclonal antibodies belonging to a research
field known as immuno-neurology, which uses the body's immune
system to fight neurodegeneration, GlaxoSmithKline said.
One of the two antibodies under development, named AL001, is in
Phase 3 trials to investigate it in a form of dementia, with
results expected at the end of 2023, the company said. The other,
named AL1010, is in early-stage trials and is being studied for the
treatment of diseases including Parkinson's and Alzheimer's,
GlaxoSmithKline said.
The company said the deal aligns with its
research-and-development focus on immunology, a therapeutic area
that GlaxoSmithKline is leveraging alongside vaccines, HIV,
oncology and respiratory, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 02, 2021 07:44 ET (11:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Jan 2025 to Feb 2025
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Feb 2025
